Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

TELA Bio (TELA) EBIAT (2018 - 2026)

TELA Bio has reported EBIAT over the past 8 years, most recently at -$9.0 million for Q4 2025.

  • For Q4 2025, EBIAT rose 1.81% year-over-year to -$9.0 million; the TTM value through Dec 2025 reached -$38.8 million, down 2.62%, while the annual FY2025 figure was -$38.8 million, 2.62% down from the prior year.
  • EBIAT for Q4 2025 was -$9.0 million at TELA Bio, down from -$8.6 million in the prior quarter.
  • Over five years, EBIAT peaked at -$5.7 million in Q1 2024 and troughed at -$12.9 million in Q4 2023.
  • A 5-year average of -$10.0 million and a median of -$10.2 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: soared 52.93% in 2024 and later tumbled 98.98% in 2025.
  • Year by year, EBIAT stood at -$8.6 million in 2021, then fell by 15.78% to -$10.0 million in 2022, then decreased by 29.17% to -$12.9 million in 2023, then increased by 28.56% to -$9.2 million in 2024, then increased by 1.81% to -$9.0 million in 2025.
  • Business Quant data shows EBIAT for TELA at -$9.0 million in Q4 2025, -$8.6 million in Q3 2025, and -$9.9 million in Q2 2025.